About the group

The Research group of prostate cancer consists of urologists and oncologists (main members) and physicians and scientists from other departments and institutes (associated members), engaged in prostate cancer research at Oslo University Hospital (OUH) and Akershus University Hospital (Ahus). Main topic of clinical research is new diagnostic methods, outcomes studies and Quality of Life studies after primary treatment and salvage treatment of prostate cancer.

The main aims for our translational research are detection and validation of new putative biomarkers in tumor tissue, blood and urine. This effort focuses on achieving a more personalized treatment of patients, in order to reduce overdiagnosis and overtreatment of prostate cancer, but also to improve diagnosis and treatment of high-risk prostate cancer.

Ongoing projects

Ongoing clinical projects where main members of the group are involved:

  • The FARP study: This is a randomized controlled trial comparing focal prostate ablation (focal HIFU) to radical prostatectomy has now completed its follow-up phase, and the results are eagerly awaited.
  • The prePSMA study (PhD project Lars Qvigstad): Preoperativ PSMA PET/CT as triage for RALP patients scheduled for ePLND. The study is recruiting well both at OUS and Ahus
  • PeP-RALP (PhD project Shivanthe Sivanesan): The impact of beta-adrenerg signalling in recurrence and metastasis in prostate cancer. This feasibility study has finished recruiting last year.
  • Short- and long-term oncological and functional outcomes after radical prostatectomy (PhD project Daniyal Noor)
  • SPCG-17. Prostate Cancer Active Surveillance Trigger Trial. The SPCG-17 study has now completed recruitment, with over 2,000 patients enrolled across five countries. At OUS, a total of 123 patients have been included, and the study is now entering the follow-up phase
  • NORAPP studien (PhD project Maciej Jacewicz): Norwegian randomized study on antibiotic propylaxis in transperineal prostate biopsy
  • The Oslo model: Development and evaluation of a lymph node invasion prediction model
  • SPCG-19: A randomized, controlled, open-label, prospective, multicenter intervention trial of immediate curative therapy versus conservative treatment in older patients with non-metastatic, high-risk prostate cancer.

Cooperation

National

  • IMBV, UiO, Fahri Saatcioglu
  • Urologisk avd. Ahus
  • Urologisk avdeling, St. Olavs sykehus, Helena Bertilsson, May–Britt Tessem
  • Kreftforskningsinstituttet, OUS. Kristin Tasken, Alicia Llorente
  • Kreftregisteret

International

  • Department of Urology, Vivantes Klinikum Am Urban, Berlin, Germany
  • Johns Hopkins School of Medicine, USA
  • Queen University, Belfast, UK
  • Martini Hospital, Hamburg, Germany
  • University College Dublin, Irland
  • University College of London

Selected Publications

  • Lilleby et al: Acute and long-term toxicity in primary hypofractionated external photon radiation therapy in patients with localized prostate cancer. World J Urol. 2024 Jan 20;42(1):41
  • Qvigstad et al: Reduction of lower urinary tract symptoms in prostate cancer patients treated with robot assisted laparoscopic prostatectomy. Scand J Urol. 2024 Jun 18;59:121-125.
  • Jacewicz et al: Non-infectious adverse events of transperineal prostate biopsies performed under local anaesthesia. BJU Int, 2024 Aug;134(2):300-306.